6.1 A complete history and physical examination including 
documentation of all measurable disease, especially involvement 
of the peritoneum and other site of initial bulk disease which 
were established initially. A dental examination is also 
recommended . 
6.2 Laboratory studies include CBC, platelet count, differential, SMA 
12, liver and renal function tests, coagulation studies (PT, PTT, 
Fibrinogen, FSP) , and cytogenetics. RT PCR for MDR-1 will be 
conducted as outlined above. 
6.3 Bone marrow aspirate and biopsy for morphology, pathology, and 
cytogenetics. Immunohistochemical analysis for the presencer of 
breast cancer cells will be conducted as outlined in Appendix G. 
In addition, a bone scan will be conducted for the presence of 
bone marrow involvement. 
6.4 An EKG and CXR will be performed on all patients. A urinalysis 
will also be obtained before therapy. 
6.5 Pulmonary function studies with diffusion capacity. 
6.6 A CT scan will be conducted to evaluate the extent of disease. 
EVALUATION DURING STUDY (SEE APPENDIX F) 
7.1 CBC, platelet, differential every 1-2 days during the initial 
induction. 
7.2 SMA 12, electrolytes every three to seven days and as indicated 
additionally. 
7.3 Bone marrow aspirate and biopsy for morphologic pathology, 
cytogenetics, and PCR for MDR-1 should be performed at marrow 
recovery (when ANC > 2000/cu mm) . 
7.4 Upon marrow recovery after transplant, a full work-up including 
CBC, platelet count and differential, SMA 12, and marrow studies 
including cytogenetics will be performed. Studies at remission 
will include CBC, platelet count, differential and SMA 12 every 
4 weeks, marrow studies with cytogenetics every 6 months and as 
indicated by disease status. 
A CBC will be conducted TIW during the period following each 
course of Taxol in order to determine the depth and duration of 
the nadirs following each course of Taxol. 
7.5 Disease status will be evaluated after recovery from autologous 
bone marrow transplant, but before the initiation of the Taxol 
therapy so as to be able to separate the effect of the transplant 
from the effect of the post transplant Taxol on the disease 
status. This will involve a CT scan of sites which are known to 
be involved with breast cancer. Twelve courses of Taxol will be 
given in the event that no residual disease is detectable 
following the transplant. 
7.6 The following will be collected before and after vector exposure 
and after hematopoietic recovery and on a six monthly basis for 
Recombinant DNA Research, Volume 19 
